Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$7.81
▲ $0.20 (+2.6%)
Market data updated: 10/02 01:23 AM
News analyzed: 10/02/2026
Market Cap
$552.86M
Day Range
$6.99 - $8.25
52-Week Range
$1.70 - $22.00
Beta
—
Next Earnings
—
Support
$1.96
Resistance
$7.89
YDES is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-57.0% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 9/15 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟢 Bullish
Technical Trend
🟢 Bullish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Price vs. SMA 50
Price is above the 50-day average
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 11.5% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
The stock YDES carries an investorScore of 81 and a STRONG rating, reflecting a generally positive technical backdrop tempered by notable risk factors. Technically, the price sits above both its 50‑day and 200‑day moving averages and a positive MACD histogram signals upward momentum, which underpins the high technical score of 83. However, the RSI at 77.1 and %K at 94.9 indicate the instrument is approaching overbought territory, suggesting the rally may face short‑term pressure. News sentiment is exceptionally favorable, with a perfect 100 score derived from multiple headlines highlighting broader market gains and sector‑specific optimism, which reinforces the bullish outlook. In contrast, the risk score is low at 34, driven by a high ATR (11.8% of price) that points to elevated short‑term volatility and a Calmar ratio of –0.44, reflecting a three‑year annualized return of –40.3% and a maximum drawdown of 91.8%. These risk metrics flag substantial downside potential despite the recent 235.2% three‑month outperformance versus the index. Overall, the combination of strong trend indicators and positive news drives the high composite score, while the elevated volatility and poor historical risk‑adjusted returns keep the risk assessment modest, creating a nuanced picture of strength coupled with caution.
Price above 50‑day and 200‑day averages, positive MACD histogram, but RSI and %K are in overbought zones.
Trend confirmation supports momentum while overbought signals warn of possible pullbacks.
All news signals are neutral to positive, contributing to a perfect news score of 100.
Favorable market sentiment can sustain buying pressure.
High ATR (11.8% of price) and a negative Calmar ratio (-0.44) indicate high volatility and poor risk‑adjusted returns.
Elevated risk may erode gains if adverse moves occur.
StockIQ conclusion
YDES displays solid technical strength and enjoys strong positive news sentiment, which together lift its overall score. Yet, high short‑term volatility and a historically poor risk profile temper enthusiasm, indicating that while the stock is currently in a favorable position, investors should monitor overbought signals and risk metrics closely.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
78
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $7.81
Evidence: +3.8pp vs. sector average today
What happened after
Still awaiting outcome
today · $7.81
Evidence: 6 insider open-market buy(s) in the last 30 days
What happened after
Still awaiting outcome
today · $7.81
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
today · $7.81
Evidence: 9 bullish / 4 bearish technical signals agreeing
What happened after
Still awaiting outcome
today · $7.80
Evidence: +5.6pp vs. sector average today
What happened after
Still awaiting outcome
today · $8.09
Evidence: +9.3pp vs. sector average today
What happened after
Still awaiting outcome
today · $7.42
Evidence: +4.2pp vs. sector average today
What happened after
Still awaiting outcome
today · $7.42
Evidence: 3 insider open-market buy(s) in the last 30 days
What happened after
Still awaiting outcome
today · $7.42
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
today · $7.42
Evidence: 10 bullish / 3 bearish technical signals agreeing
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of October 1, 2026
Then
81
$7.42
Now
78
$7.81
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
78
Risk
34
Sentiment
100
Fundamental
No data available
Institutional
100
Stocks with a similar DNA right now
🕵️ What the Detective found on YDES
Detective Score 90/100 · 3 signals convergingOverall, the signals found here lean positive.
🧠 What the Detective thinks
כרגע המניה YDES של חברת YD Bio מראה שלושה סיגנלים חזקים ומתכנסים: היא נמצאת במגמת עלייה ברורה ללא הגבלות טכניות, מה שמצביע על תנופה חזקה. בנוסף, ישנן פעולות של 'חכמים בשוק' — שלושה רכישות של מניות על ידי אנשי מפתח בשוק הפתוח האחרון, שיכולות להעיד על אמון פנימי. יחד עם זאת, הסיגנלים הטכניים והפעילות של אנשי מפתח מתאימים זה לזה, מה שמקנה למניה תדמית של תנועה מונעת על ידי כוחות חיוביים.
What this means now: Several different technical indicators are currently agreeing on the same direction at once — that's unusual; most days they contradict each other.
Why it matters: When several technical indicators agree at once, that's usually more reliable than any single indicator alone.
What this means now: The price has formed a distinct technical structure (a trading range, shakeout, or breakout) that the Wyckoff method treats as a key moment where big money is building or unwinding a position.
Why it matters: May provide an additional indication of trading structure, but is not proof of future direction.
What this means now: Company directors or executives bought shares on the open market, with their own money, in the last month — not options, a real purchase.
Why it matters: Open-market insider buys are a real action with real money, not just an opinion.
📊 Historically, this signal type
This is not a prediction and not investment advice — just a plain-language read of real, already-computed signals. Full details: Stock Detective →
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of YD Bio Limited has focused on its strategic initiatives in Taiwan, particularly its physician-partnership program and the launch of two new nutraceutical products in collaboration with local health organizations. Additionally, the company has been recognized for its peer-reviewed research on a computational framework for keratoconus, though broader financial or operational updates remain sparse in available sources. No recent stock performance or major financial milestones are explicitly mentioned.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about YD Bio Limited. News trend score: 100. Reason: 11 of the last 14 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
74
🎯 Conviction (vs. Emotion)
50
Psychology
83
Fundamentals
—
Technical
78
Valuation
—
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+306%
Market Narrative
88
Fundamental Reality
50
Narrative Gap
+38
🧠 StockIQ Psychologist
The market behavior here is dominated by herding, with YDES’ price movement nearly identical to its peers (+4.8% vs. +4.4%), suggesting traders are aligning with broader sector momentum rather than independent analysis. The extreme euphoria (score 81) and FOMO (80) signals—driven by 90%+ ROC, overbought RSI, and 100/100 sentiment—indicate investors may be overestimating tailwinds, while the 38-point narrative gap (88 vs. 50) hints at a disconnect between hype and fundamentals. The key question is whether this synchronized buying reflects genuine conviction or a speculative bubble propped up by momentum chasing. Anchoring (3.7% below resistance) could reinforce near-term support, but the lack of panic (score 14) despite volatility suggests traders remain complacent despite stretched metrics.
Updated: 10/01/2026, 01:28 AM
What could change this?
👥 What the crowd believes
"YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute"
"YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services"
"YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research"
"YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada"
🧠 Market Brain events driving this
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Thorstein Veblen — 80/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect a clash between methodologies that prioritize qualitative growth signals and those that emphasize quantitative caution or market psychology. Thorstein Veblen and Jesse Livermore’s high scores (80 and 79) suggest the stock aligns with their principles—Veblen’s focus on real value creation and Livermore’s technical trend confirmation—while the rest of the frameworks struggle with data gaps or red flags. Benjamin Graham, Philip Fisher, and Peter Lynch all hit the midpoint (50) due to insufficient fundamentals, but their absence of deeper conviction contrasts sharply with the outright warnings from Howard Marks (26, 29) and Gerald Loeb (21), who flag valuation risks and overbought conditions. Meanwhile, the lowest scores (0 from Nelson and Housel) highlight cyclical overreach and volatility, while Charles Mackay’s 16 points to speculative crowd behavior—all of which clash with the bullish signals from Veblen and Livermore.
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 80
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 77
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 46
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 42
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 28
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 25
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 21
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 14
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 0
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 277 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 4 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 11 positive, 2 neutral, 1 negative out of the last 14 articles.
ChartMill · 28.9.2026
Benzinga · 28.9.2026
Benzinga · 28.9.2026
Benzinga · 28.9.2026
Benzinga · 25.9.2026
Benzinga · 25.9.2026
Benzinga · 25.9.2026
ChartMill · 24.9.2026
GlobeNewswire · 11.8.2026
GlobeNewswire · 4.8.2026
GlobeNewswire · 28.7.2026
GlobeNewswire · 23.7.2026
ChartMill · 22.7.2026
GlobeNewswire · 2.7.2026
StockIQ doesn't currently have enough real data to compute a reliable score for YD Bio Limited (YDES) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for YDES specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
YDES's technical score is 78/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Price is above the 50-day average; Price is above the 200-day average; MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: ATR: 11.5% of price; Calmar: -0.45 (3y annualized return -41.5% / max drawdown 91.8%); RSI 76.0 — approaching overbought territory.
StockIQ has no recorded dividend payment history for YDES.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 6 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Shen Ethan PhD | Open Market Purchase | 14.9.2026 | 12,700 | +12,700 | $3.85 |
| Shen Ethan PhD | Open Market Purchase | 14.9.2026 | 11,258,331 | +12,700 | $3.85 |
| Shen Ethan PhD | Open Market Purchase | 9.9.2026 | 3,100 | +3,100 | $3.93 |
| Shen Ethan PhD | Open Market Purchase | 9.9.2026 | 11,245,631 | +3,100 | $3.93 |
| Shen Ethan PhD | Open Market Purchase | 4.9.2026 | 18,378 | +18,378 | $3.67 |
| Shen Ethan PhD | Open Market Purchase | 4.9.2026 | 11,242,531 | +18,378 | $3.67 |
| Lu Shao-Ta | Exercise of Derivative Securities | 30.6.2026 | 5,749 | +5,749 | — |
| Chang Kochi | Exercise of Derivative Securities | 30.6.2026 | 5,749 | -5,749 | — |
| Lu Shao-Ta | Grant/Award from Employer | 30.6.2026 | 5,749 | +5,749 | — |
| Lu Shao-Ta | Exercise of Derivative Securities | 30.6.2026 | 5,749 | -5,749 | — |
| Chang Kochi | Grant/Award from Employer | 30.6.2026 | 5,749 | +5,749 | — |
| Chang Kochi | Exercise of Derivative Securities | 30.6.2026 | 5,749 | +5,749 | — |
| Chang Kochi | Exercise of Derivative Securities | 30.6.2026 | 7,830 | +5,749 | — |
| Chang Kochi | Grant/Award from Employer | 30.6.2026 | 5,749 | +5,749 | — |
| Chang Kochi | Exercise of Derivative Securities | 30.6.2026 | 0 | -5,749 | — |
| Lu Shao-Ta | Exercise of Derivative Securities | 30.6.2026 | 7,830 | +5,749 | — |
| Lu Shao-Ta | Grant/Award from Employer | 30.6.2026 | 5,749 | +5,749 | — |
| Lu Shao-Ta | Exercise of Derivative Securities | 30.6.2026 | 0 | -5,749 | — |
| Chang Kochi | Exercise of Derivative Securities | 31.3.2026 | 2,081 | +2,081 | — |
| Chang Kochi | Grant/Award from Employer | 31.3.2026 | 2,081 | +2,081 | — |
| Lu Shao-Ta | Grant/Award from Employer | 31.3.2026 | 2,081 | +2,081 | — |
| Lu Shao-Ta | Exercise of Derivative Securities | 31.3.2026 | 2,081 | +2,081 | — |
| Chang Kochi | Exercise of Derivative Securities | 31.3.2026 | 2,081 | +2,081 | — |
| Lu Shao-Ta | Exercise of Derivative Securities | 31.3.2026 | 2,081 | +2,081 | — |
| Chang Kochi | Exercise of Derivative Securities | 31.3.2026 | 2,081 | +2,081 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
42,960 shares short as of 2026-09-15 · vs. 13,293 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
47.8% of trading volume this week was short selling, vs. 58.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology